CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons

@article{Tefferi2014CALRVJ,
  title={CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons},
  author={A. Tefferi and T. Lasho and C. Finke and R. Knudson and R. Ketterling and C. Hanson and M. Maffioli and D. Caramazza and F. Passamonti and A. Pardanani},
  journal={Leukemia},
  year={2014},
  volume={28},
  pages={1472-1477}
}
Calreticulin (CALR) mutations were recently described in JAK2 and MPL unmutated primary myelofibrosis (PMF) and essential thrombocythemia. In the current study, we compared the clinical, cytogenetic and molecular features of patients with PMF with or without CALR, JAK2 or MPL mutations. Among 254 study patients, 147 (58%) harbored JAK2, 63 (25%) CALR and 21 (8.3%) MPL mutations; 22 (8.7%) patients were negative for all three mutations, whereas one patient expressed both JAK2 and CALR mutations… Expand
View on Nature
ncbi.nlm.nih.gov
390 Citations
Highly Influential Citations
14
Background Citations
82
Methods Citations
5
Results Citations
9

Paper Mentions

News Article
Geron: Of Abstracts And Abstractions
Seeking Alpha
9 November 2018

390 Citations

Citation Type

Citation Type

JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis
  • 14
  • Highly Influenced
  • PDF
Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia
  • 52
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.
  • 270
  • PDF
Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia
  • 18
  • PDF
Co-existence of JAK2 V617F and CALR mutations in primary myelofibrosis
  • 18
Different CALR mutation subtypes in essential thrombocythemia and primary myelofibrosis patients without JAK2 mutation
CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms
  • 7
CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
  • 66
  • PDF
Coexisting JAK2V617F and CALR Exon 9 Mutation in Essential Thrombocythemia
  • 7
CALR mutations screening in wild type JAK2(V617F) and MPL(W515K/L) Brazilian myeloproliferative neoplasm patients.
  • 16
  • Highly Influenced
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
EZH2 mutational status predicts poor survival in myelofibrosis.
  • 220
  • PDF
IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F
  • 140
  • PDF
Mutations and prognosis in primary myelofibrosis
  • 510
  • PDF
SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival.
  • 138
Somatic mutations of calreticulin in myeloproliferative neoplasms.
  • 1,376
  • PDF
Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance
  • 112
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.
  • 1,290
  • PDF
Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival.
  • 58
Leukemia Risk Models in Primary Myelofibrosis: An International Working Group Study,
  • 18
  • PDF
Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients
  • 141
  • PDF
...
1
2
3
4
...